vTv Therapeutics (NASDAQ:VTVT) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last year.
Related Posts
Seaport Global Upgrades Hibbett to Buy, Announces $75 Price Target
Seaport Global analyst Mitch Kummetz upgrades Hibbett (NASDAQ:HIBB) from Neutral to Buy and announces $75 price target.
Nuvation Bio Q1 EPS $(0.10) Up From $(0.12) YoY
Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.10) per share. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year.